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BACKGROUND
Experimental and clinical evidence supports the role of inflammation in athero-
sclerosis and its complications. Colchicine is an orally administered, potent anti-
inflammatory medication that is indicated for the treatment of gout and pericarditis.
METHODS
We performed a randomized, double-blind trial involving patients recruited within 
30 days after a myocardial infarction. The patients were randomly assigned to receive 
either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end 
point was a composite of death from cardiovascular causes, resuscitated cardiac ar-
rest, myocardial infarction, stroke, or urgent hospitalization for angina leading to 
coronary revascularization. The components of the primary end point and safety were 
also assessed.
RESULTS
A total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine 
group, and 2379 to the placebo group. Patients were followed for a median of 22.6 
months. The primary end point occurred in 5.5% of the patients in the colchicine 
group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% 
confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 
0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for 
resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 
(95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospi-
talization for angina leading to coronary revascularization. Diarrhea was reported in 
9.7% of the patients in the colchicine group and in 8.9% of those in the placebo 
group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the 
patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03).
CONCLUSIONS
Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg 
daily led to a significantly lower risk of ischemic cardiovascular events than placebo. 
(Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov num-
ber, NCT02551094.)
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I nflammation appears to play an im-portant role in atherosclerosis.1 Inhibition of interleukin-1β by the injectable monoclonal 
antibody canakinumab led to a 15% lower risk of 
cardiovascular events than was observed with 
placebo in the Canakinumab Antiinflammatory 
Thrombosis Outcomes Study (CANTOS) but also 
led to a slightly higher incidence of fatal infec-
tions.2 In contrast, methotrexate did not affect 
cardiovascular outcomes or plasma markers of in-
flammation in the Cardiovascular Inflammation 
Reduction Trial (CIRT).3 In light of these differing 
results and given that canakinumab has not been 
approved for cardiovascular prevention, the search 
for a widely used alternative antiinflammatory 
treatment that may reduce the risk of atheroscle-
rotic events among patients with coronary artery 
disease continues.
Colchicine is an inexpensive, orally adminis-
tered, potent antiinflammatory medication that 
was initially extracted from the autumn crocus and 
has been used for centuries. Its mechanism of ac-
tion is through the inhibition of tubulin polymer-
ization and microtubule generation and, possibly, 
effects on cellular adhesion molecules, inflamma-
tory chemokines, and the inflammasome.4-6 Col-
chicine is currently indicated for the treatment of 
gout, familial Mediterranean fever, and pericardi-
tis.7,8 In the Low-Dose Colchicine (LoDoCo) trial, 
patients with stable coronary disease treated with 
colchicine at a dose of 0.5 mg once daily had 
fewer cardiovascular events than those not receiv-
ing colchicine.9 However, that trial enrolled only 
532 patients and was not placebo-controlled. Be-
cause acute coronary syndromes are associated 
with higher risks of recurrent events and exacer-
bated inflammation, we conducted the Colchicine 
Cardiovascular Outcomes Trial (COLCOT) to evalu-
ate the effects of colchicine on cardiovascular 
outcomes as well as its long-term safety profile 
in patients who had recently had a myocardial 
infarction.
Me thods
Trial Design and Oversight
In this randomized, double-blind, placebo-con-
trolled, investigator-initiated trial, we assigned 
patients in a 1:1 ratio to receive either colchicine 
(at a dose of 0.5 mg once daily) or placebo. The 
trial was funded by the Government of Quebec, 
the Canadian Institutes of Health Research, and 
philanthropic foundations. The trial protocol, 
available with the full text of this article at NEJM 
.org, was designed by the trial steering committee. 
The protocol was approved by the institutional 
review board at each of the 167 centers in the 12 
countries that participated in the trial (see the 
Supplementary Appendix, available at NEJM.org). 
All trial support activities, including project co-
ordination, medical review, data management, site 
monitoring, and statistical oversight and analyses, 
were performed at the Montreal Health Innova-
tions Coordinating Center. Potential trial end-point 
events were adjudicated by an independent clini-
cal end-point committee composed of experienced 
cardiologists and neurologists who were unaware 
of the trial-group assignments. The trial was over-
seen by a data and safety monitoring board of in-
dependent experts. The trial medication and 
matching placebo were provided by Pharmasci-
ence, which had no role in the design or conduct 
of the trial or in the preparation or review of the 
manuscript. The first author and the lead statis-
tician (also an author) prepared the first draft of 
the manuscript, had full access to the trial data-
base, and generated statistical analyses; they 
also made the decision to submit the manuscript 
for publication and assume responsibility for the 
accuracy and completeness of the data and for 
the fidelity of the trial to the protocol.
Trial Population
Adult patients were eligible if they had had a 
myocardial infarction within 30 days before en-
rollment, had completed any planned percutane-
ous revascularization procedures, and were treat-
ed according to national guidelines that included 
the intensive use of statins. Patients were excluded 
if they had severe heart failure, a left ventricular 
ejection fraction of less than 35%, stroke within 
the previous 3 months, a type 2 index myocardial 
infarction, coronary-bypass surgery either within 
the previous 3 years or planned, a history of non-
cutaneous cancer within the previous 3 years, 
inflammatory bowel disease or chronic diarrhea, 
neuromuscular disease or a nontransient creatine 
kinase level that was greater than three times 
the upper limit of the normal range (unless due 
to infarction), clinically significant nontransient 
hematologic abnormalities, severe renal disease 
with a serum creatinine level that was greater than 
two times the upper limit of the normal range; 
severe hepatic disease, drug or alcohol abuse, cur-
rent or planned long-term systemic glucocorticoid 
therapy, or a history of clinically significant sen-
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sitivity to colchicine. (Details regarding eligibility 
criteria are provided in the Supplementary Ap-
pendix.)
Written informed consent was obtained from 
all the patients before enrollment. Clinical eval-
uations occurred at 1 month and 3 months after 
randomization and every 3 months thereafter.
End Points
The primary efficacy end point was a composite 
of death from cardiovascular causes, resuscitated 
cardiac arrest, myocardial infarction, stroke, or 
urgent hospitalization for angina leading to coro-
nary revascularization in a time-to-event analysis. 
The secondary end points consisted of the com-
ponents of the primary efficacy end point; a 
composite of death from cardiovascular causes, 
resuscitated cardiac arrest, myocardial infarc-
tion, or stroke; and total mortality in time-to-
event analyses. Coronary revascularization, hos-
pitalization for heart failure, atrial fibrillation, 
and deep venous thrombosis or pulmonary em-
bolus were prespecified as exploratory end points 
in the protocol. Additional prespecified explor-
atory end points included the change from base-
line to 6 months in the high-sensitivity C-reactive 
protein level and the change from baseline to 12 
months in the white-cell count. The C-reactive 
protein biomarker substudy was implemented after 
a protocol amendment and was optional for sites 
and for patients; 34 sites chose to participate in 
this substudy.
All serious adverse events were recorded. The 
only other adverse events recorded were those that 
were considered to be related to the gastrointes-
tinal system, events that were judged by the in-
vestigator to be related to colchicine or placebo, 
or laboratory abnormalities that had been judged 
by the investigator to be clinically significant.
Statistical Analysis
In this event-driven trial, it was estimated that a 
sample of approximately 4500 patients undergo-
ing randomization (with 2250 patients in each 
group) or, in terms of events, a total number of 
301 patients with a first positively adjudicated 
primary end-point event would yield adequate 
power. The sample-size calculation was based 
on the primary efficacy end point and assumed 
a 27% lower risk with colchicine than with pla-
cebo, indicated by a hazard ratio of 0.724. With 
the use of a two-sided test at the 0.05 significance 
level, the trial would have 80% power if it con-
tinued until 301 positively adjudicated primary 
events occurred in the combined trial groups. 
The trial design assumed an event rate of 7% in 
the placebo group at 24 months, an 18-month 
recruitment period during which patients would 
be uniformly recruited, a 24-month minimum 
follow-up period, and a 1% annual rate of loss to 
follow-up or withdrawal of consent.
The efficacy analyses were conducted with 
the use of positively adjudicated data and accord-
ing to the intention-to-treat principle. The pri-
mary end point was compared between the two 
trial groups with the use of a log-rank test, and 
the hazard ratio, with a 95% confidence interval, 
was calculated from a Cox proportional-hazards 
model. A Cox proportional-hazards model with 
adjustment for important baseline characteristics 
was also used as prespecified in the protocol. 
The analysis of the primary end point was re-
peated in the per-protocol population (i.e., patients 
without major protocol deviations). Secondary and 
exploratory end points expressed as time to event 
were analyzed similarly. The changes from base-
line to follow-up were analyzed with the use of 
an analysis of covariance model with adjustment 
for baseline value, and estimates of treatment ef-
fect are presented with 95% confidence intervals.
The efficacy end points expressed as time to 
event could be assessed in all patients because 
the event dates and censoring dates were com-
plete, with the exception of one incomplete event 
date for atrial fibrillation; therefore, imputation 
for missing data was not done. In the analysis of 
time to event, the following censoring rules were 
used. For death from any cause and death from 
cardiovascular causes, data from event-free pa-
tients who completed the trial were censored at the 
date of trial completion, and data from patients 
who did not complete the trial, such as those who 
were lost to follow-up or who withdrew consent, 
were censored at the date of last contact or the 
date of the assessment of survival status, which-
ever was later. For the analysis of death from 
cardiovascular causes, patients who died from a 
noncardiovascular cause had their data censored 
at the time of death. For all other end points, 
including the primary end point, the same cen-
soring rules applied, but the survival status was 
not used because no formal assessment of end 
points was done at the assessment of survival 
status. An analysis of the components of the pri-
mary end point with death from noncardiovascular 
causes as a competing event for death from cardio-
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vascular causes, and with death from any cause as 
a competing event for the other components, was 
conducted with the use of the Fine and Gray sub-
distribution hazard model.10 No missing data were 
imputed except for age in cases in which informa-
tion on the day or the month and day of birth was 
missing. To account for the occurrence of multiple 
primary end-point events within patients, recur-
rent-event analyses were undertaken with the use 
of negative binomial regression, Andersen–Gill, 
and Wei–Lin–Weissfeld models.11-19
An interim analysis was performed after 50% 
of the primary end-point events had been posi-
tively adjudicated. The prespecified stopping rule 
for efficacy was based on the Lan–DeMets pro-
cedure with the O’Brien–Fleming alpha-spending 
function. After review of the interim results, the 
data and safety monitoring board recommended 
that the trial should continue as planned. To ac-
count for this interim analysis, the statistical 
significance level was set to 0.0490 for the final 
analysis of the primary end point. All other sta-
tistical tests were two-sided and conducted at the 
0.05 significance level. Statistical analyses were 
performed with the use of SAS software, version 
9.4 (SAS Institute). There was no prespecified plan 
to adjust for multiple comparisons across the mul-
tiple methods that were used to analyze the pri-
mary and secondary end points; results of these 
analyses are reported with point estimates and 
95% confidence intervals, without P values. The 
95% confidence intervals were not adjusted for 
multiple comparisons, and inferences drawn from 
them may not be reproducible. The final amend-
ment to the statistical analysis plan was approved 
on August 28, 2019, before unblinding of the trial-
group assignments occurred.
R esult s
Patients
Trial enrollment began in December 2015 and 
was completed in August 2018; the last trial visit 
was in July 2019. A total of 4745 patients under-
went randomization (with 2366 being assigned 
to the colchicine group and 2379 to the placebo 
group) and were followed for a median of 22.6 
months. At the time of the database lock on 
August 28, 2019, and unblinding on August 29, 
2019, vital status was available for all except 23 
patients (99.5%); 89 patients (1.9%) were lost to 
follow-up, and 30 patients (0.6%) withdrew con-
sent. Details regarding the disposition of the pa-
tients are provided in Figure 1.
The characteristics of the patients at baseline 
are shown in Table 1. Patients were enrolled a 
mean of 13.5 days after myocardial infarction. 
The mean age of the patients was 60.6 years, 
19.2% of the patients were women, and 20.2% 
had diabetes. Most patients (93.0%) underwent 
percutaneous coronary intervention for their index 
myocardial infarction. Aspirin, a different anti-
platelet agent, and a statin were taken by 98.8%, 
97.9% and 99.0% of the patients, respectively.
At the end of the trial, the trial regimen had 
been discontinued in 18.4% of the patients in the 
colchicine group and in 18.7% of those in the pla-
cebo group. Among the patients who discontinued 
the trial regimen, the median duration of receipt of 
the trial drug was 7.1 months (interquartile range, 
1.9 to 14.6) in the colchicine group, as compared 
with 6.1 months (interquartile range, 1.6 to 14.4) 
in the placebo group. Overall, the median dura-
tion of receipt of the trial drug was 19.6 months 
in the colchicine group and 19.5 months in the 
placebo group.
Clinical Efficacy End Points
A primary end-point event occurred in 5.5% of the 
patients in the colchicine group, as compared with 
Figure 1. Randomization and Follow-up of the Patients.
4745 Patients underwent randomization
2379 Were assigned to receive placebo
(33 did not receive placebo)
Survival status at end of trial:
2325 Were alive
44 Had died
10 Had unknown survival status
2232 Completed the trial
147 Did not complete the trial
13 Withdrew consent
38 Discontinued placebo and
visits
1 Had an adverse event
50 Were lost to follow-up
44 Died
1 Discontinued trial prematurely
and did not complete all visits
2366 Were assigned to receive colchicine
(36 did not receive colchicine)
Survival status at end of trial:
2309 Were alive
44 Had died
13 Had unknown survival status
2226 Completed the trial
140 Did not complete the trial
17 Withdrew consent
41 Discontinued colchicine and 
visits
39 Were lost to follow-up
42 Died
1 Had been hospitalized since
October 10, 2018
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7.1% of those in the placebo group (hazard ratio, 
0.77; 95% confidence interval [CI], 0.61 to 0.96; 
P = 0.02 by the log-rank test). A multivariable Cox 
regression model with adjustment for baseline 
covariates yielded a similar result (Table S1 in the 
Supplementary Appendix). The event curves that 
were based on a Kaplan–Meier analysis of the 
primary efficacy end point are shown in Figure 2. 
In the prespecified per-protocol analysis involving 
patients who adhered to the protocol, the primary 
end point occurred in 5.1% of the patients in the 
colchicine group and in 7.1% of those in the pla-
cebo group (hazard ratio, 0.71; 95% CI, 0.56 to 
0.90) (Table S2). Table 2 shows the percentages 
of patients with events and the hazard ratios for 
the components of the primary end point, includ-
ing death from cardiovascular causes (hazard ra-
tio, 0.84; 95% CI, 0.46 to 1.52), resuscitated car-
diac arrest (hazard ratio, 0.83; 95% CI, 0.25 to 
2.73), myocardial infarction (hazard ratio, 0.91; 
95% CI, 0.68 to 1.21), stroke (hazard ratio, 0.26; 
95% CI, 0.10 to 0.70), and urgent hospitalization 
for angina leading to coronary revascularization 
(hazard ratio, 0.50; 95% CI, 0.31 to 0.81). The 
hazard ratios remained unchanged in the analy-
sis that took competing events into account.
The secondary efficacy end point consisting 
of a composite of death from cardiovascular 
causes, cardiac arrest, myocardial infarction, or 
stroke occurred in 4.7% of the patients in the 
colchicine group and in 5.5% of those in the 
placebo group (hazard ratio, 0.85; 95% CI, 0.66 
to 1.10). Data on the primary, secondary, and 
exploratory efficacy end points are provided in 
Table 2. Two patients had a first positively adju-
dicated event of urgent hospitalization for angi-
na leading to coronary revascularization within 
14 days after randomization. The median time 
to this clinical end point was 258 days. Efficacy 
results in prespecified subgroups are shown in 
Characteristic
Colchicine 
(N = 2366)
Placebo 
(N = 2379)
Age — yr 60.6±10.7 60.5±10.6
Female sex — no. (%) 472 (19.9) 437 (18.4)
White race — no./total no. (%)† 1350/1850 (73.0) 1329/1844 (72.1)
Body-mass index 28.2±4.8 28.4±4.7
Current smoking — no./total no. (%) 708/2366 (29.9) 708/2377 (29.8)
Hypertension — no. (%) 1185 (50.1) 1236 (52.0)
Diabetes — no. (%) 462 (19.5) 497 (20.9)
History of myocardial infarction — no. (%) 370 (15.6) 397 (16.7)
History of PCI — no. (%) 392 (16.6) 406 (17.1)
History of CABG — no. (%) 69 (2.9) 81 (3.4)
History of heart failure — no. (%) 48 (2.0) 42 (1.8)
History of stroke or TIA — no. (%) 55 (2.3) 67 (2.8)
Time from index myocardial infarction to randomization — days 13.4±10.2 13.5±10.1
PCI for index myocardial infarction — no./total no. (%) 2192/2364 (92.7) 2216/2375 (93.3)
Medication use — no. (%)
Aspirin 2334 (98.6) 2352 (98.9)
Other antiplatelet agent 2310 (97.6) 2337 (98.2)
Statin 2339 (98.9) 2357 (99.1)
Beta-blocker 2116 (89.4) 2101 (88.3)
*  Plus–minus values are means ±SD. Data were missing on the following characteristics: age (assessed according to 
date of birth; see below) for 435 patients (215 in the colchicine group and 220 in the placebo group), body-mass index 
(the weight in kilograms divided by the square of the height in meters) for 5 (1 and 4 patients, respectively), and infor-
mation about the index myocardial infarction for 6 (2 and 4 patients, respectively). Date of birth and race were not re-
quired fields because both were considered in some countries to be sensitive data that could allow for the identification 
of patients. For statistical reporting, missing information regarding the day of birth was replaced by 15, and missing in-
formation regarding the month and day of birth was replaced by July 1. CABG denotes coronary-artery bypass graft sur-
gery, PCI percutaneous coronary intervention, and TIA transient ischemic attack.
†  Race was reported by the patient.
Table 1. Characteristics of the Patients.*
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Table S3. The total number of primary end-point 
events (first and recurrent) was 154 in the col-
chicine group and 223 in the placebo group, over 
periods of 52,949 and 53,060 patient-months of 
follow-up, respectively. Thus, the primary end-
point event rates per 100 patient-months were 
0.29 in the colchicine group and 0.42 in the pla-
cebo group (rate ratio, 0.66; 95% CI, 0.51 to 0.86) 
(Table S4).
Biomarkers of Inflammation
High-sensitivity C-reactive protein was measured 
in a subgroup of only 207 patients at the time of 
randomization and 6 months later, and the me-
dian concentration at trial entry was 4.28 mg per 
liter. The baseline characteristics of these patients 
were similar to those of the overall population 
(Table S5), but the small and selected subgroup 
with these data limits the interpretation of these 
analyses. The adjusted geometric mean percent 
changes in the high-sensitivity C-reactive protein 
level at 6 months after myocardial infarction 
were −70.0% in the colchicine group and −66.6% 
in the placebo group, and the placebo-adjusted 
Figure 2. Cumulative Incidence of Cardiovascular Events (Intention-to-Treat 
Population).
Shown are the Kaplan–Meier event curves for the primary efficacy com-
posite end point of death from cardiovascular causes, resuscitated cardiac 
arrest, myocardial infarction, stroke, or urgent hospitalization for angina 
leading to coronary revascularization in the colchicine group and the place-
bo group in a time-to-event analysis. The inset shows the same data on an 
enlarged y axis.
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End Point
Colchicine 
(N = 2366)
Placebo 
(N = 2379)
Hazard Ratio 
(95% CI) P Value
number (percent)
Primary composite end point 131 (5.5) 170 (7.1) 0.77 (0.61–0.96) 0.02†
Components of primary end point
Death from cardiovascular causes 20 (0.8) 24 (1.0) 0.84 (0.46–1.52)
Resuscitated cardiac arrest 5 (0.2) 6 (0.3) 0.83 (0.25–2.73)
Myocardial infarction 89 (3.8) 98 (4.1) 0.91 (0.68–1.21)
Stroke 5 (0.2) 19 (0.8) 0.26 (0.10–0.70)
Urgent hospitalization for angina lead-
ing to revascularization
25 (1.1) 50 (2.1) 0.50 (0.31–0.81)
Secondary composite end point‡ 111 (4.7) 130 (5.5) 0.85 (0.66–1.10)
Death 43 (1.8) 44 (1.8) 0.98 (0.64–1.49)
Deep venous thrombosis or pulmonary 
embolus
10 (0.4) 7 (0.3) 1.43 (0.54–3.75)
Atrial fibrillation 36 (1.5) 40 (1.7) 0.93 (0.59–1.46)
*  Only the initial event was counted in the analyses of time to first event for the primary composite end point and for the 
secondary composite end point. In the component analysis, the different types of events were counted separately.
†  The log-rank test and the multivariable Cox proportional-hazards model including age, history of diabetes, previous cor-
onary revascularization, and previous heart failure yielded similar P values.
‡  The secondary composite end point included death from cardiovascular causes, resuscitated cardiac arrest, myocardial 
infarction, and stroke.
Table 2. Major Clinical End Points (Intention-to-Treat Population).*
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geometric mean percent change was −10.1 per-
centage points in the colchicine group (95% CI, 
−28.6 to 13.4) (Table S6).
Information about white-cell counts at baseline 
and at the 12-month follow-up were also available 
for a relatively small subgroup of 1972 patients. 
The adjusted geometric mean percent changes 
from baseline to 1 year in the total white-cell count 
were −18.8% in the colchicine group and −19.0% 
in the placebo group, with no significant dif-
ference between groups (0.3 percentage points; 
95% CI, −2.2 to 2.7).
Safety and Adverse Events
The incidence of adverse events that were consid-
ered to be related to the active drug or placebo was 
16.0% in the colchicine group and 15.8% in the 
placebo group, and the overall incidence of serious 
adverse events was 16.4% and 17.2%, respectively 
(Table 3). At least one gastrointestinal adverse 
event during the double-blind period occurred in 
17.5% of the patients in the colchicine group, as 
compared with 17.6% of those in the placebo 
group. Diarrhea was reported in 9.7% of the pa-
tients in the colchicine group and in 8.9% of 
those in the placebo group (P = 0.35), and nausea 
was more common in the colchicine group than 
in the placebo group (1.8% vs. 1.0%, P = 0.02). 
Pneumonia was reported as a serious adverse event 
in 0.9% of the patients in the colchicine group, 
as compared with 0.4% of those in the placebo 
group (P = 0.03).
Discussion
In COLCOT, the risk of the primary composite 
efficacy end point of death from cardiovascular 
causes, resuscitated cardiac arrest, myocardial 
infarction, stroke, or urgent hospitalization for 
angina leading to coronary revascularization, as 
assessed in a time-to-event analysis, was signifi-
cantly lower among the patients who were ran-
domly assigned to receive 0.5 mg of colchicine 
once daily than among those who received place-
bo. This result was due predominantly to a lower 
incidence of strokes and urgent hospitalizations 
for angina leading to coronary revascularization.
These results were observed against a back-
ground of appropriate medications, which includ-
ed aspirin, a different antiplatelet agent, and a 
statin in 98 to 99% of the patients. In addition, 
percutaneous coronary intervention was performed 
in 93% of the patients for their index myocar-
dial infarction. The benefits of colchicine with 
regard to cardiovascular end points in COLCOT 
were at least as large as those of canakinumab 
in CANTOS.2 In the small subgroup of patients 
with available data, as expected, a large (>65%) 
reduction in the C-reactive protein level occurred 
over the first 6 months after myocardial infarc-
Event
Colchicine 
(N = 2330)
Placebo 
(N = 2346) P Value
number of patients (percent)
Any related adverse event† 372 (16.0) 371 (15.8) 0.89
Adverse events
Gastrointestinal event 408 (17.5) 414 (17.6) 0.90
Diarrhea 225 (9.7) 208 (8.9) 0.35
Nausea 43 (1.8) 24 (1.0) 0.02
Flatulence 15 (0.6) 5 (0.2) 0.02
Gastrointestinal hemorrhage 7 (0.3) 5 (0.2) 0.56
Anemia 14 (0.6) 10 (0.4) 0.40
Leukopenia 2 (0.1) 3 (0.1) 0.66
Thrombocytopenia 3 (0.1) 7 (0.3) 0.21
Serious adverse events
Any serious adverse event‡ 383 (16.4) 404 (17.2) 0.47
Gastrointestinal event 46 (2.0) 36 (1.5) 0.25
Infection 51 (2.2) 38 (1.6) 0.15
Pneumonia 21 (0.9) 9 (0.4) 0.03
Septic shock 2 (0.1) 2 (0.1) 0.99
Hospitalization for heart  
failure
25 (1.1) 17 (0.7) 0.21
Cancer§ 43 (1.8) 46 (2.0) 0.77
*  The safety population was defined as patients who took at least one dose of 
colchicine or placebo. All serious adverse events were recorded, and the only 
other adverse events recorded were those that were related to the gastrointes-
tinal system, events that were judged by the investigator to be related to col-
chicine or placebo, or laboratory abnormalities that were judged by the inves-
tigator to be clinically significant. This table lists serious adverse events that 
were present in more than 2% of the patients in either trial group, adverse 
events that were considered to be related to colchicine or placebo in more 
than 5% of the patients in either trial group, and any other safety events of 
special interest. Chi-square tests were conducted to compare the incidence  
of adverse events between the trial groups.
†  These adverse events were considered to be related to colchicine or placebo 
by the physician in charge of the participant.
‡  There was one serious adverse event of myopathy, which was attributed to 
high-dose statin therapy (rosuvastatin at a dose of 40 mg daily) by the local 
investigator and academic sponsor, in a man of short stature (165 cm, 68 kg) 
with normal renal function in the colchicine group who had received colchi-
cine for 8 days 3 months before the adverse event.
§  Cancers, excluding nonmelanoma skin cancers, occurred in 42 patients 
(1.8%) in the colchicine group and in 44 (1.9%) in the placebo group.
Table 3. Adverse Events (Safety Population).*
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on February 14, 2020. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;26 nejm.org December 26, 20192504
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
tion in both trial groups in COLCOT, but the dif-
ference between the changes in the groups was 
not significant. These findings must be interpreted 
cautiously given that this was a small subgroup 
that was not randomly selected from the full trial 
sample. A similar observation was made with 
white-cell counts. The different patient popula-
tions involved in the two trials — early after 
myocardial infarction in COLCOT and stable 
coronary disease in CANTOS — may also have 
affected the relationship between biomarkers of 
inflammation and the effects of treatments on 
ischemic end points.
The known benefits of colchicine in the treat-
ment of pericarditis were not at play in COLCOT. 
Postinfarction pericarditis typically occurs with-
in the first few days after the injury, whereas the 
mean time from the index myocardial infarction 
to randomization was 13.5 days. There were only 
two patients with a first positively adjudicated 
event of urgent hospitalization for angina lead-
ing to coronary revascularization within 14 days 
after randomization, and the median time to this 
clinical end point was 258 days.
The most common adverse events observed 
were gastrointestinal. Diarrhea was reported in 
9.7% of the patients in the colchicine group and 
in 8.9% of those in the placebo group, and nausea 
occurred in 1.8% and 1.0%, respectively. Infection 
as a serious adverse event was more frequent in 
the colchicine group than in the placebo group 
(in 2.2% vs. 1.6% of the patients), and pneumonia 
as a serious adverse event was also more fre-
quent in the colchicine group (0.9% vs. 0.4%). 
These differences in the incidence of infections 
could be due to the play of chance or could re-
flect altered immunologic responses. In contrast 
to canakinumab,2 colchicine did not increase the 
incidence of septic shock in our trial. Infections 
have previously been described in patients who 
have attempted suicide by taking an overdose of 
colchicine.20 There was no serious adverse event 
of myopathy linked to colchicine despite the use 
of statins in 99% of the patients in the trial.
Our trial has certain limitations. The duration 
of follow-up was relatively short at approximately 
23 months. The risks and benefits of longer-term 
treatment with colchicine were not evaluated. 
Although the inclusion of 4745 patients was suf-
ficient for the trial to show a significant benefit 
with regard to the primary composite efficacy end 
point, a larger trial could have allowed a better 
assessment of individual end points and subgroups 
and the risks associated with colchicine. Finally, 
our results apply only to patients who have re-
cently had a myocardial infarction.
In conclusion, among patients with a recent 
myocardial infarction, colchicine at a dose of 
0.5 mg daily led to a significantly lower percent-
age of patients with ischemic cardiovascular events 
than placebo.
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